Sunday, April 21, 2024
HomeBharat NewsJitendra Singh: Team Biotech Develops The World’s 1st Intranasal Vaccine For COVID.

Jitendra Singh: Team Biotech Develops The World’s 1st Intranasal Vaccine For COVID.

Last updated on July 15th, 2023 at 04:50 pm

Estimated reading time: 2 minutes

New Delhi: Union Minister Jitendra Singh said that Team Biotech has developed the world’s first intranasal vaccine for COVID. Appreciating the team for their efforts, the Minister said that the Department of Biotechnology (DBT) under the Ministry and its PSU, Biotechnology Industry Research Assistance (BIRAC) has made a major contribution to the development.

Singh said that the personal intervention and regular monitoring of Prime Minister Narendra Modi have made this possible. This launch made Mission Covid Suraksha possible, which strengthened Atmanirbhar Bharat and cemented India’s position as a vaccine development and manufacturing hub across the world. It refers to an event that showcased India’s science and technology capabilities.

He said that the Department of Biotechnology and BIRAC have funded the product development and clinical trials under Mission Covid Suraksha. This vaccine has been approved for restricted use in emergency situations in a primary two-dose schedule for adults aged 18 and over.

The National Institute of Immunology (NII) in New Delhi, an autonomous institute under the Department of Biotechnology, has developed a human immune surveillance and T-cell immunoassay platform for screening of vaccine-induced SARS-CoV-2-specific systemic and mucosal cellular immunity. Have done Reactions. “The Ministry of Science and Technology said that the test participants were great.”

“Plaque Reduction Neutralization Assay” (PRNT) was completed by Interactive Research School for Health Affairs (IRSHA), Pune (supported by DBT BIRAC) to quantify the titer of neutralizing antibodies to the virus from three test sites.

The vaccine is a replication-deficient adenovirus vector vaccine that has a pre-fusion stabilized spike protein. This vaccine candidate was successfully evaluated in Phase I, II, and III clinical trials.

This formula is designed to be delivered intranasally through nasal drops. The vaccine is stable at 2-8°C for easy storage and distribution, said the Ministry.

Google News

Latest Stories

- Advertisment - NIT Infotech